Symbols

CDXS

Codexis·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 1

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CDXS

Codexis, Inc.

A leading enzyme engineering company enabling the promise of synthetic biology

Industry

Pharmaceutical

Established Date

Listing Date

04/22/2010

Exchange

NASDAQ Stock Exchange

Full-time Employees

146

Fiscal Year Ends

12-31

Website

www.codexis.com

Security Type

Common stock

Office address

200 Penobscot Drive Redwood City California 94063

Business

Introduction

Codexis, Inc., incorporated in Delaware in January 2002, is a leading provider of technology solutions dedicated to improving the manufacture of therapeutic drugs. The Company utilizes its proprietary CodeEvolver directed evolution technology platform to discover, develop, enhance and commercialize novel high-performance enzymes and other types of proteins. These enzymes are indispensable biomolecules in almost all biochemical reactions and can be engineered to give them specific functions and properties. Codexis applies its technology and expertise to improve the properties and performance of enzymes and drives significant advancements in the production process of complex therapeutic drugs through its ECO synthesis platform and small molecule drug biocatalysis business.

Company Financials

EPS

CDXS has released its 2025 Q4 earnings. EPS was reported at 0.11, versus the expected -0.04, beating expectations. The chart below visualizes how CDXS has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

CDXS has released its 2025 Q4 earnings report, with revenue of 38.91M, reflecting a YoY change of 81.34%, and net profit of 9.60M, showing a YoY change of 192.53%. The Sankey diagram below clearly presents CDXS's revenue sources and cost distribution.